Literature DB >> 6322680

Ceftriaxone levels in blood and tissue during cardiopulmonary bypass surgery.

C S Bryan, S L Morgan, A B Jordan, C W Smith, J P Sutton, J D Gangemi.   

Abstract

One gram of ceftriaxone was given intravenously to 15 patients approximately 2 h before cardiopulmonary bypass surgery. Ceftriaxone levels in plasma (mean +/- standard deviation) were 60.4 +/- 18.8 micrograms/ml (range, 17.0 to 96.0 micrograms/ml) at the beginning of bypass, 44.2 +/- 16.6 micrograms/ml (range, 9.4 to 78.6 micrograms/ml) at the end of bypass, and 19.6 +/- 9.6 micrograms/ml (range, 4.2 to 47.1 micrograms/ml) the following morning, 18.1 to 24.7 h after infusion of ceftriaxone. Concentrations in the sternal bone were 4.7 +/- 2.1 micrograms/g (range, 1.0 to 10.1 micrograms/g; tissue-to-plasma ratios, 0.066 +/- 0.036). Concentrations in the atrial appendage were 7.7 +/- 1.8 microgram/g (range, 3.6 to 10.2 micrograms/g; tissue-to-plasma ratios, 0.143 +/- 0.062). These data suggest that a single dose of ceftriaxone might be useful for prevention of infection due to susceptible pathogens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322680      PMCID: PMC185430          DOI: 10.1128/AAC.25.1.37

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  The use of linear models and matrix least squares in clinical chemistry.

Authors:  S N Deming; S L Morgan
Journal:  Clin Chem       Date:  1979-06       Impact factor: 8.327

2.  Determination of cephalosporins in biological material by reversed-phase liquid column chromatography.

Authors:  A M Brisson; J B Fourtillan
Journal:  J Chromatogr       Date:  1981-05-08

3.  Comparative in vitro activities of third-generation cephalosporins.

Authors:  R J Fass
Journal:  Arch Intern Med       Date:  1983-09

4.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

5.  Ceftriaxone: in vitro studies and clinical evaluation.

Authors:  J W Gnann; W E Goetter; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

6.  Mediastinitis after cardiovascular surgery.

Authors:  D H Bor; R M Rose; J F Modlin; R Weintraub; G H Friedland
Journal:  Rev Infect Dis       Date:  1983 Sep-Oct

7.  Wound infection in cardiothoracic surgery.

Authors:  F C Wells; S W Newsom; C Rowlands
Journal:  Lancet       Date:  1983-05-28       Impact factor: 79.321

8.  Bacteremia following prosthetic valve replacement.

Authors:  F B Parker; C Greiner-Hayes; R H Tomar; A H Markowitz; E L Bove; M A Marvasti
Journal:  Ann Surg       Date:  1983-02       Impact factor: 12.969

9.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

10.  Comparison of cefamandole and cefazolin during cardiopulmonary bypass.

Authors:  C S Bryan; C W Smith; J P Sutton; W B Allen; R Blanding; J D Gangemi
Journal:  J Thorac Cardiovasc Surg       Date:  1983-08       Impact factor: 5.209

  10 in total
  2 in total

Review 1.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 2.  Preventing deep wound infection after coronary artery bypass grafting: a review.

Authors:  Charles S Bryan; William M Yarbrough
Journal:  Tex Heart Inst J       Date:  2013
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.